| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-09 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-08 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-07 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-06 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-06 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |